MarketMoodz
AZN and GSK Q1 Beat as MFN Pricing Looms in Europe
AstraZeneca and GSK posted stronger-than-expected Q1 profits, signaling resilience despite pricing-policy headwinds. The most-favored-nation pricing proposal in the United States could tie European prices to U.S. levels, potentially squeezing margins and threatening new medicines launches. Investors will be watching how this dynamic shapes guidance through 2026.
Key Takeaways
- AZN Q1 revenue $15.3B, up 8% YoY, beating $14.9B consensus.
- AZN core EPS $2.58, vs $2.53 expected.
- GSK Q1 revenue £7.63B ($10.3B), up 5% YoY, in line with expectations.
- GSK core EPS £0.47, vs £0.43 expected.
- MFN pricing could link European prices to U.S. levels, risking launches; Trump MFN policy context adds pressure.
People Involved
- Pascal SoriotChief Executive Officer, AstraZeneca
- Vas NarasimhanChief Executive Officer, Novartis
Entities Involved
- AstraZeneca (AZN)British-Swedish pharmaceutical company
- GSK (GSK)British multinational pharmaceutical company
- Novartis (NVS)Swiss multinational pharmaceutical company
MarketMoodz Analysis
The Q1 beat underscores that AstraZeneca and GSK can grow profits amid pricing-policy risk. While top-line strength supports margins and dividend discipline, the MFN framework in the U.S. could compress European pricing power and dampen upside from upcoming pipeline milestones in cancer and respiratory programs.
Narasimhan’s caution that MFN reality could start impacting in about 18 months provides a rough timetable for investors. The sector will likely reassess guidance, capital allocation, and potential M&A as payers converge pricing, making near-term performance less about one quarter and more about how companies manage cost of goods, R&D productivity, and portfolio evolution through 2026.
Source: Original Article